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The kinase inhibitor D11 induces caspase-
mediated cell death in cancer cells resistant
to chemotherapeutic treatment
Barbara Guerra1*, Mette Fischer1, Susanne Schaefer1 and Olaf-Georg Issinger2
Abstract
Background: Multi-drug resistance and predisposition to metastasize are major clinical problems in cancer treatment.
Malignant primary brain tumor and pancreatic cancer are two well-known examples of malignant tumors resistant to
conventional therapies where aberrant EGFR-mediated and NF-κB signal transduction pathways are likely to play
an important role. We have recently identified 1,3-Dichloro-6-[(E)-((4-methoxyphenyl)imino)methyl] diben-zo(b,d)
furan-2,7-diol (D11) as a potent and selective inhibitor of CK2 a serine/threonine protein kinase that modulates
the aforementioned signaling cascades.
Methods: Human cancer cell lines (glioblastoma and pancreatic adenocarcinoma) resistant to conventional
chemotherapeutic agents were incubated with increasing concentrations of D11 for variable amounts of time. Cell
viability, cell death and effects on major signal transduction pathways deregulated in cancer cells were analyzed by
ELISA, FACS and Western blot-based assays, respectively. Moreover, effects on cell migration and in cell protein-protein
association were investigated by wound-healing and in situ proximity ligation assays, respectively.
Results: We show here, that D11 treatment leads to i) significant caspase-mediated apoptotic cell death, ii) down-
regulation of EGFR expression and iii) inhibition of NF-κB transcriptional activity. Furthermore, cell exposure to D11
results in impaired cell migration and correlates with reduced expression of the ion co-transporter and cell volume
regulator Na+-K+-2Cl− (NKCC1).
Conclusions: Data reported here underline the therapeutic potential of D11 with respect to certain types of cancer
that carry aberrant intracellular signaling cascades and/or exhibit sustained cell migration and suggest a new therapeutic
strategy against chemotherapy resistance.
Keywords: Kinase inhibitors, EGFR, NF-κB, NKCC1, ROCK, Apoptosis, Glioblastoma, Pancreatic adenocarcinoma
Background
Cancer is a disease characterized by genomic alterations
that confer a selective growth advantage to cancer cells.
In recent years, large-scale multi-dimensional analysis of
clinical data has provided a detailed map of the major
molecular alterations occurring during cancer develop-
ment and led to two important observations: i) tumors
originating from the same type of tissue or organ display
significant differences with respect to genomic alter-
ations and ii) tumors with different origin bear common
genetic alterations that result in enhanced survival, pro-
liferation and drug resistance [1, 2]. The epidermal growth
factor receptor (EGFR) signaling is a major regulator of
cell survival and motility (reviewed in [3]). Overexpression
or mutation of EGFR is often responsible for tumor resist-
ance to both chemotherapy and radiotherapy [4–9]. Re-
sistance of tumors overexpressing EGFR is linked to
aberrant phosphoinositide 3-kinase (PI3K)/AKT pathway,
a key signal transduction system that links multiple recep-
tor classes and oncogenes [10, 11]. Recent cancer genomic
studies have revealed that multiple components of the
PI3K pathway are frequently targeted by germline or som-
atic mutations [12–14]. In this respect, the tumor suppres-
sor phosphatase and tensin homolog (PTEN) and AKT
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are found frequently mutated in cancer ([15] and reviewed
in [16]). The nuclear factor-κB (NF-κB) signaling pathway
is often constitutively activated in cancer due to mutations
in the genes coding for NF-κB isoforms or in those
coding for proteins (e.g. IκBα) that control NF-κB ac-
tivity [4, 6, 11].
We have recently identified 1,3-Dichloro-6-[(E)-((4-
methoxyphenyl)imino)methyl] diben-zo(b,d) furan-2,7-
diol (referred to as D11) as a novel potent and selective
inhibitor of protein kinase CK2 from a screening of 1600
compounds of the Diversity Set III from the DTP pro-
gram of the NCI/NIH [17]. Protein kinase CK2 is a
constitutively active serine/threonine protein kinase
whose expression and activity has been found elevated
in all so far investigated tumors and highly proliferating
tissues (reviewed in [18, 19]). Interestingly, CK2 modulates
the PI3K/AKT signaling cascade by targeting AKT and
PTEN for phosphorylation. Moreover, it regulates the
NF-κB pathway by promoting IκB degradation and NF-κB
phosphorylation that results in enhanced DNA binding
and transcriptional activity of the latter [20–23].
In this study, we have analyzed the potency and bio-
chemical mechanisms of cell death induction of D11 on
glioblastoma and pancreatic adenocarcinoma cells that
are characterized by aberrant EGFR/PI3K and NF-κB sig-
naling pathways and resistance towards radio- and chemo-
therapy [24–27]. Results reported here show that D11
exerts potent anti-tumor effects warranting further in vivo
studies for validating its efficacy against multi-drug resist-
ant cancer cells.
Materials and methods
Cell culture and treatments
The human glioblastoma cell lines M059K and U-87
MG and the human pancreatic adenocarcinoma cell
line MIA PaCa-2 were purchased from the American
Type Culture Collection (ATCC, Rockville, MD, USA)
and cultivated at 37 °C under a 5 % CO2 atmosphere in
Dulbecco’s modified Eagle’s medium (DMEM, Invitro-
gen, Taastrup, Denmark) supplemented with 10 % fetal
bovine serum (FBS, Biochrom AG, Berlin, Germany).
MIA PaCa-2 cells were additionally cultivated in the
presence of 2.5 % horse serum (Biochrom AG). Cells
were treated with D11 (DTP, NIH/NCI, Rockville, MD,
USA), IGF-1 (Calbiochem, Nottingham, UK) and TNFα
(R&D Systems, Abingdon, UK) as indicated in the fig-
ure legends. Cell transfection was carried out with Li-
pofectamine 3000 reagent (Life Technologies, Naerum,
Denmark) according to the manufacturer’s guidelines
and a plasmid carrying the coding region for farnesy-
lated AKT devoid of the PH domain prepared accord-
ing to [28]. The correct sequence and orientation were
verified by DNA sequencing. Neocarzinostatin (NCS)
was kindly provided by Dr. Hiroshi Maeda, Kumamoto
University, Japan.
Determination of cell viability
D11-mediated cytotoxicity was determined by the WST-1
viability assay (Roche, Hvidovre, Denmark). Viability was
quantified in a microtiter plate reader (VersaMax ELISA,
Molecular Devices, Sunnyvale, CA, USA) after adding the
WST-1 reagent to the cells according to the manufac-
turer’s guidelines.
Flow cytometry analysis
Cell cycle analysis and determination of cell death was
determined as previously described [29]. The analysis
was carried out on a FACS-Calibur flow cytometer (BD
Biosciences, San Jose, CA, USA). Acquired data were
processed by Cell Quest Pro Analysis software (BD Bio-
sciences). For each measurement, 10,000 events were
analyzed.
Preparation of whole cell lysate, Western blot analysis
and antibodies
Cells were harvested and further processed for Western
blot analysis as described in [26, 30]. The following pri-
mary antibodies were employed in the study: mouse
monoclonal anti-AKT, mouse monoclonal anti-poly
(ADPribose)polymerase (PARP), mouse monoclonal
anti-RAFT1/FRAP/mTOR (all from BD Biosciences);
mouse monoclonal anti-caspase 8, mouse monoclonal
anti-caspase 9, rabbit monoclonal anti-caspase 3, rabbit
polyclonal anti-PTEN, rabbit polyclonal anti-phospho-
PTEN (S380/T382,383), rabbit monoclonal anti-phospho-
AKT (S473), rabbit polyclonal anti-phospho-AKT (T308),
rabbit polyclonal anti-phospho-mTOR (S2481), rabbit
monoclonal anti-Raptor, rabbit polyclonal anti-phospho-
Raptor (S792), rabbit monoclonal anti-Tuberin/TSC2,
rabbit polyclonal anti-phospho-Tuberin/TSC2 (S1387),
rabbit polyclonal anti-phospho-Tuberin/TSC2 (T1462),
mouse monoclonal anti-phospho-p70S6K (T389), rabbit
polyclonal anti-phospho-AMPKα (T172), rabbit poly-
clonal anti-AMPKα, rabbit monoclonal anti-NF-κB/p65/
RelA, rabbit monoclonal anti-NF-κB/p65/RelA (S536),
rabbit monoclonal anti-phospho-IKKα/β (S176,180),
rabbit polyclonal anti-IKKα, rabbit polyclonal anti-IKKβ,
rabbit monoclonal anti-phospho-IκBα (S32), mouse
monoclonal anti-IκBα, rabbit monoclonal anti-NKCC1 (all
from Cell Signaling Technology); mouse monoclonal anti-
β-actin (Sigma-Aldrich); rabbit polyclonal anti-EGFR,
rabbit polyclonal anti-p70S6K, rabbit polyclonal anti-
HSP90, mouse monoclonal anti-CDC37 (all from Santa
Cruz Biotechnology, Heidelberg, Germany); rabbit poly-
clonal anti-phospho-NKCC1 (T212,217), rabbit polyclonal
anti-AKT1 (both from Millipore, Billerica, MA, USA) and
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rabbit polyclonal anti-phospho-NF-κB p65 (S529, Abcam,
Cambridge, MA, USA).
Immunostaining and in situ proximity ligation assay
Cells grown on coverslips were fixed with 4 % paraformal-
dehyde for 15 min, permeabilized with 0.1 % Na-citrate,
0.1 % Triton X-100, pH 7 for 5 min and, where indicated,
counterstained with 4′,6′-diamidino-2-penylindole (DAPI,
Sigma-Aldrich, Brøndby, Denmark). Actin filaments where
visualized by Alexa Fluor 488 phalloidin staining (Invitro-
gen) for 20 min at room temperature according to the
manufacturer’s recommendations. Localization of NF-κB
was performed by incubating the cells with rabbit monoclo-
nal anti-NF-κB/p65/RelA antibody (Cell Signaling Technol-
ogy, Herlev, Denmark) at 4 °C overnight followed by
labeling with biotinylated swine anti-rabbit immunoglobu-
lin (Dako, Glostrup, Denmark) for 1 h at room temperature
and Alexa Fluor 488-conjugated streptavidin (Life Tech-
nologies) for 30 min at room temperature. Cells were ana-
lyzed for HSP90-CDC37 interaction by in situ proximity
ligation assay (PLA, Olink Biosciences, Uppsala, Sweden)
according to the manufacturer’s recommendations. The
number of positive signals was determined using Blobfinder
software (http://www.cb.uu.se/~amin/BlobFinder). Cells
were analyzed on a Leica DMRBE microscope equipped
with a DFC 420C camera and Leica Application Suite V
3.3.0 software (Leica Microsystem, Wetzler, Germany).
Transcription factor assay
The transcriptional activity of NF-κB was measured apply-
ing the TransAM assay system kit (Active Motif, Carlsbad,
CA, USA) following the manufacturer’s recommendations.
Quantification was performed with a VersaMax ELISA
microplate reader (Molecular Devices).
ROCK kinase assay
ROCK activity was measured using the ROCK1/2 activity
assay kit (Cell Biolabs, Inc., San Diego, CA, USA). After
treatment, cells were harvested, washed in ice-cold PBS
and lysed. Kinase assay was performed according to the
manufacturer’s recommendations. Measurements were ob-
tained with a VersaMax ELISA microplate reader (Molecu-
lar Devices) using 450 nm as the primary wavelength.
Wound-healing assay
Cells were cultured in 60 mm Petri dishes until conflu-
ent. Subsequently, straight scratches were made with a
p200 pipet tip across the Petri dishes simulating a wound
[31]. Pictures were taken at different intervals as indicated
in the figure legends using phase contrast and the 5x ob-
jective on a DMIRB microscope (Leica Microsystem). Un-
healed areas were quantified using the ImageJ64 software.
Statistical and densitometric analysis
The statistical significance of differences between means
of two groups was determined by the two-tailed t-test
(Student’s t-test). The levels of significance are indicated
in the figure legends.
Results
Cytotoxic effects of D11 in cancer cell lines
Human glioblastoma cells (M059K) and human pancre-
atic adenocarcinoma cells (MIA PaCa-2) were tested for
in vitro sensitivity to D11 (Fig. 1a). The inhibitory con-
centration (IC50) was achieved with 40 μM D11 after
48 h of incubation in M059K cells while for MIA PaCa-
2 cells, similar effects were achieved with 60 μM D11
after 72 h of incubation with respect to control experi-
ments. Additionally, analysis of U-87 MG glioblastoma
cells showed that treatment with 25 μM D11 for 24 h re-
sulted in 50 % decrease in viable cells (Additional file 1:
Figure S1).
Next, cell cycle analysis was investigated by flow cy-
tometry (Fig. 1b and Additional file 2: Figure S2). Cells
were treated with various amounts of drug for 24 h
(M059K) and 48 h (MIA PaCa-2), respectively. With re-
spect to control experiments, significant differences in
the percentage of cells with reduced DNA levels (i.e.
sub-G1) were observed with 50 μM D11 (M059K) and
80 μM D11 (MIA PaCa-2) treatment, respectively. West-
ern blot analysis (Fig. 2a) indicated that 50 μM D11 in-
duces cleavage of full-length PARP in M059K cells after
24 h incubation time while significant PARP cleavage
was observed in MIA PaCa-2 cells when treated with 60
and 80 μM D11 for 48 h, respectively. Analysis of
cleavage-mediated caspase activation revealed that both
the intrinsic and extrinsic apoptotic pathways [32] are
involved in D11-induced cell death. In order to determine
whether treatment with D11 can sensitize cancer cells to-
wards conventional antitumor drugs, we incubated M059K
with the radiomimetic drug neocarzinostatin (NCS) alone
or in combination with D11. Combined treatment affected
the viability (Additional file 3: Figure S3a) and resulted
in enhanced apoptotic cell death (Additional file 3:
Figure S3b) suggesting that D11 partially sensitizes glio-
blastoma cells to NCS.
Rho-associated kinase ROCK1 is a serine/threonine
kinase that has been identified as a caspase-3 target in-
volved in the blebbing process observed in apoptosis
[33, 34]. Hence, we determined whether D11 treatment
results in enhanced ROCK kinase activity. Significant in-
crease in the phosphorylation of myosin phosphatase
target subunit 1 (MYPT1) was observed as compared to
control experiments, demonstrating that cell exposure to
D11 leads to activation of ROCK kinase in both cell
types (Fig. 2b). It has been shown that cells committed
to detachment as observed in the activation of cell death,
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often exhibit disruption of central stress fibers and a
contractile ring containing filamentous actin (F-actin) at
the cell periphery [35]. Studies performed by employing
mouse embryonic fibroblasts showed that cytoskeleton
reorganization is dependent on the expression of active
ROCK1 [36, 37]. Hence, we analyzed D11-mediated ef-
fects on actin filaments dynamics by staining cells with
phalloidin [38]. D11 treatment resulted in actin cyto-
skeleton remodeling in both cell lines characterized by
reduction of central stress fibers and formation of a
ring of filaments at the cell periphery (Fig. 2c). Overall,
results show that D11 exposure induces apoptotic cell
death at varying treatment conditions depending on
the type of cells, and that glioblastoma cells are more
Fig. 1 Anti-proliferative effects of D11 in human cancer cell lines. a M059K and MIA PaCa-2 cell lines were treated with increasing concentrations
of D11 for a variable amount of time, respectively. Control experiment refers to cells treated with vehicle (0.1 % DMSO). The proportion of viable
cells was determined by WST-1 assay and expressed in arbitrary units as a difference in absorbance measured at 450 nm and 690 nm (reference)
wavelengths, respectively (mean +/− standard deviation, N= 6). Asterisks denote statistical significant differences between control and D11-treated cells for
the corresponding time points, *, P <0.0001. b Flow cytometry analysis of cells treated with 0.1 % DMSO (Control) and increasing concentrations of D11 for
24 h (M059K) and 48 h (MIA PaCa-2), respectively. The amount of cells in the various phases of the cell cycle is indicated in percentage. Experiments were
repeated three times obtaining similar results. Data from one representative experiment are shown
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sensitive to the cytotoxic effects of D11 than pancre-
atic cancer cells.
D11 treatment suppresses pro-survival signaling
pathways
PI3K/AKT pathway
Components of the PI3K/AKT pathway were analyzed fol-
lowing short exposure to D11. Results presented in Fig. 3a
show that D11 treatment led to a significant decrease of
EGFR, mTOR, Raptor and Tuberin/TSC2 protein expres-
sion. This correlated with low phosphorylation levels of
the corresponding proteins with respect to control experi-
ments. Additionally, D11 treatment resulted in inhibition
of AKT and p70S6K kinase activity although a less pro-
nounced decrease in their expression levels was observed.
PTEN status was investigated only in MIA PaCa-2 cells.
Fig. 2 Exposure of cells to D11 leads to induction of apoptotic cell death. a Cells were treated with DMSO and increasing concentrations of D11
for 24 h (M059K) and 48 h (MIA PaCa-2), respectively. Whole cell lysate was subjected to Western blot analysis for apoptosis-associated proteins.
b Whole cell lysate from cells treated for 24 h with the indicated concentrations were subjected to ROCK kinase assay in the presence of myosin
phosphatase target subunit 1 (MYPT1). Data from one representative experiment (mean +/− standard deviation, N = 6, *, P <0.05; **, P <0.001) are
shown. c Immunofluorescence analysis of control cells (0.1 % DMSO) or cells treated with the indicated concentrations of D11 for 24 h. Actin filaments
were visualized by staining cells with phalloidin-Alexa 488. Representative images were acquired using fluorescence microscopy at 400x magnification
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Fig. 3 (See legend on next page.)
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According to Sonkin et al., M059K cells have a G-M
PTEN status assigned to cell lines with homozygous non-
sense, frame shift, known loss of function missense muta-
tion or dominant negative mutation of a specific tumor
suppressor gene [39]. The analysis revealed that D11 treat-
ment leads to decreased PTEN expression and phosphor-
ylation levels.
AMP-activated protein kinase (AMPK) is a nutrient sen-
sor responsible for cellular energy homeostasis (reviewed
in [40]). AMPK exerts dual regulatory effects on the PI3K
pathway by targeting Tuberin/TSC2, an inhibitor of mTOR
[41], and the TORC1 scaffold protein Raptor [42] for phos-
phorylation. Short exposure to D11 led to significant loss
of AMPK kinase activity, which was partially recovered
after 24 h of incubation time (Fig. 3b).
The chaperon protein HSP90 (heat shock protein 90)
promotes folding, trafficking and stability of more than
200 client proteins including ErbB2, EGFR, Raf, MEK,
FAK, PTEN, AKT, Raptor and mTOR [43–46]. Chaper-
ones’ function is dependent on the presence of co-
chaperone proteins and co-activators [47]. CK2-dependent
phosphorylation of the co-chaperone CDC37, has been
shown to be necessary for HSP90-CDC37 heterocomplex
stabilization with client protein kinases (reviewed in [48]).
As treatment with D11 resulted in down-regulation of
HSP90 client proteins, we analyzed the association be-
tween HSP90 and CDC37 by in situ proximity ligation
assay. As shown in Fig. 3c, cell exposure to D11 resulted in
significant decrease in signal intensity with respect to con-
trol cells suggesting that the observed decrease in expres-
sion of components of the PI3K signaling pathway may be
due to destabilization of HSP90-CDC37 heterocomplex.
NF-κB pathway
NF-κB comprises a family of proteins existing as homo-
or heterodimers whose aberrant expression and/or activ-
ity have been associated with various types of solid
tumors (reviewed in [49]). Within the canonical activation
pathway, the NF-κB signaling is controlled by the tumor
necrosis factor receptor leading to activation of IκB
kinase (IKK) complex, which in turn phosphorylates IκBα.
It follows IκBα degradation and activation of NF-κB
(reviewed in [50]). D11 treatment in combination with
TNFα led to decreased phosphorylation of NF-κB/p65 at
S536 and S529 amino acid residues as well as the up-
stream IKKα/β at S176/180. Interestingly, D11 treatment
almost completely reversed IκBα degradation induced by
TNFα suggesting impaired TNFα-mediated activation
of the NF-κB pathway (Fig. 4a and Additional file 4:
Figure S4). NF-κB activation downstream of EGFR-
dependent signaling is regulated by mechanisms involving
directly AKT and the TORC2 (Rictor-mTOR) complex,
respectively [51–53]. AKT functions through IKK to pro-
mote the phosphorylation and transactivation potential of
NF-κB [54]. Moreover, it has been shown that the AKT-
dependent TORC1 (Raptor-mTOR)/IKK interaction stimu-
lates IKK activity which results in the phosphorylation of
IκBα and activation of NF-κB [55]. We analyzed whether
overexpression of constitutively active AKT reversed D11-
mediated inhibition of NF-κB in cells treated with TNFα.
As shown in Fig. 4b, the expression of constitutively active
AKT (farn-AKT) was unable to reverse NF-κB inhibition as
the levels of IKKβ-mediated phosphorylation of NF-κB at
S536 as well as the CK2-mediated phosphorylation of S529
were essentially the same in cells transfected with empty
vector or a vector expressing farn-AKT. As D11 is not a
direct inhibitor of AKT, mTOR, IKKα/β [17, 33, 34, 56], re-
sults reported above suggest that D11 treatment inhibits
the NF-κB-dependent signaling by targeting molecule(s)
other than the aforementioned proteins. Next, we analyzed
whether D11 affects NF-κB migration and transcriptional
activity induced by TNFα. Exposure of cells to TNFα for
10 min promptly resulted in NF-κB nuclear localization in
both cell lines (Fig. 5a). However, additional treatment with
D11 inhibited significantly TNFα-induced translocation of
NF-κB in MIA PaCa-2 cells and only marginally in the case
of M059K cells. To further support these results, we ana-
lyzed effects of D11 on the transcriptional activity of NF-κB
induced by TNFα. D11 treatment significantly inhibited the
transcriptional activity of NF-κB in MIA PaCa-2 and U-87
MG cells (Fig. 5b). However, consistent with results re-
ported in Fig. 5a, a modest but significant inhibition was
observed in the case of M059K cells.
(See figure on previous page.)
Fig. 3 Analysis of the PI3K pathway in cells treated with D11. a Whole cell lysates from the indicated cell lines were subjected to Western blot
analysis. Expression and/or phosphorylation of the indicated proteins were analyzed after 5 h incubation with D11. Control experiments (−) refer
to cells incubated with vehicle (0.1 % DMSO). b Cells were treated with vehicle (−) or 50 μM (M059K) and 70 μM (MIA PaCa-2) D11, respectively,
for the indicated times. Whole cell lysates were subjected to Western blot analysis of phosphorylated AMPK and AMPK protein. β-actin detection
was used as a control for equal loading. c Association between HSP90 and CDC37 was revealed in M059K by in situ proximity ligation assay
(PLA). NC refers to untreated cells subjected to PLA where one of the primary antibodies was omitted. Determination of the number of signals
per cell as distinct red fluorescence spots indicative of HSP90-CDC37 proximity, was performed by computer-assisted image analysis as described in
the Materials and methods. Nuclei were visualized by DAPI staining (blue fluorescence emission). Experiments were repeated at least three times
obtaining similar results. The figure includes a schematic representation of the EGFR/PI3K signaling network in mammalian cells (*, P <0.05)
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Fig. 4 Cell incubation with D11 impairs activation of the NF-κB signaling pathway induced by TNFα. a Whole cell lysates from cells treated with
50 μM (M059K) and 70 μM D11 (MIA PaCa-2), respectively, for 5 h and stimulated with 20 ng/ml TNFα for 10 min prior harvesting, were analyzed
by Western blot. The expression and phosphorylation levels of members of the NF-κB signaling pathway are shown. b MIA PaCa-2 cells transiently
transfected with either empty vector (EV) or a construct containing farnesylated AKT devoid of the PH domain (ΔPH-AKT-farn) were treated as
described in (a). Expression and activation of NF-κB as well as AKT were verified by Western blot analysis of whole cell lysates. β-actin detection
was used as loading control. The figure shows a schematic model of the canonical NF-κB signaling pathway
Guerra et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:125 Page 8 of 14
Fig. 5 D11-mediated effects on the transcriptional activity of NF-κB. a Cells were treated as described in Fig. 4 and Additional file 4: Figure S4.
Subcellular localization of NF-κB was detected by immunofluorescence staining of cells with rabbit monoclonal anti-NF-κB antibody (green fluorescence,
Alexa Fluor 488). Nuclei were visualized by DAPI staining. NC, negative control refers to cells stained with biotinylated secondary antibody and Alexa Fluor
488 streptavidin, only. Original magnification: 400x. b NF-κB transcriptional activity was determined as described in Materials and methods. The indicated
cell lines were treated as described in Fig. 4. Asterisks denote statistical significant differences in TNFα-induced NF-κB activity in the absence or presence
of D11 (N= 6, *, P <0.05). Experiments were repeated at least three times obtaining similar results
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Cell incubation with D11 impairs cell migration and
correlates with down-regulation of the Na+-K+-2Cl−
co-transporter (NKCC1)
Stimulation of EGFR controls migration through acti-
vation of the PI3K/AKT signaling cascade (reviewed in
[36, 37, 57–59]). Interestingly, AKT has been shown
to control cell motility through phosphorylation and
activation of WNK kinases (With No K-lysine), which
regulate the ion co-transporter NKCC1 a modulator of
migration in glioma cells [17, 57, 60–63]. As treatment
of cells with D11 resulted in decreased EGFR expres-
sion levels, we assessed whether this correlated with
decreased cell migration. A wound-healing assay was
carried out measuring cell-unwounded areas after
varying incubation times with D11 according to the
speed of cell migration. Results reported in Fig. 6a
show that the presence of D11 significantly impaired
the ability of both cell types to migrate. In the case of
M059K cells, treatment with 50 μM D11 led to about
27 % decrease in the wounded area 16 h post-wounding. In
control experiments, the wounded area decreased about
79 %. Control MIA PaCa-2 cells decreased the wounded
area 65 % at 36 h post-wounding while treatment with
70 μM D11 for 36 h led to approx. 52 % increase in the
wounded area suggesting impaired migration and, add-
itionally, cell death induction. Next, NKCC1 phosphoryl-
ation levels were determined in cells left untreated or
exposed to D11, IGF-1 or a combination of both, respect-
ively. Results in Fig. 6b show that D11 treatment led to de-
creased phosphorylation of NKCC1 at T212/217, the
major activating site in NKCC1 [17, 58, 64], while EGFR
activation by the pro-migratory IGF-1 [60, 62, 65, 66] did
not reverse effects induced by the presence of D11. How-
ever, analysis of NKCC1 expression indicated that D11
treatment leads to significant down-regulation of NKCC1
protein expression levels.
Discussion
EGFR gene amplification and mutation occur with high
frequency in glioma (40–63 %) and pancreatic cancer
(30–50 %). NF-κB, typically the p50-RelA/p65 heterodi-
mer, is frequently activated in the aforementioned types
of cancer resulting in enhanced cell proliferation and
suppression of apoptosis. Two common mechanisms ap-
pear to contribute to NF-κB activation: i) deletion of the
NFKBIA gene which encodes IκBα and ii) EGFR amplifi-
cation. Given the importance of the EGFR and NF-κB
signaling in the control of cell proliferation, survival and
motility, substantial evidence suggests that these path-
ways may be useful targets for treatment.
In this study, we have tested the ability of a small mol-
ecule compound, D11, previously identified through a
large screening of a small molecule compound library,
to induce cell death in glioblastoma and pancreatic
cancer cells and explored effects induced on the afore-
mentioned signaling pathways. We show that D11 treat-
ment results in caspase-dependent activation of cell
death, which correlates with increased activity of ROCK
kinase. This is in line with previous data showing that
caspase 3-cleaved ROCK1, phosphorylates myosin light
chains that is a necessary event for the formation of dy-
namic membrane protrusions consistently observed in
apoptosis [17, 33, 34, 56, 67]. Analysis of the actin cyto-
skeleton revealed actin filaments remodeling following
D11 treatment characterized by the formation of a cor-
tical ring of actin filaments at the cell periphery accom-
panied by the disappearance of central stress fibers
(Fig. 2c). Surma et al., demonstrated that ROCK1 and
ROCK2 play different roles in the regulation of stress
fiber dynamics, ROCK1 being responsible for the dis-
ruption of central stress fibers in doxorubicin-treated
cells [36, 37, 57]. Similarly, data reported here suggest
that actin cytoskeleton rearrangement induced by D11
is mediated by ROCK1 activation.
Treatment with D11 led to inhibition of the EGFR/
PI3K signaling cascade. Protein expression analysis indi-
cated that one of the reported effects was a significant
down-regulation of HSP90-client proteins such as EGFR,
PTEN, mTOR, Raptor and Tuberin/TSC2. D11 has been
shown to be an effective inhibitor of protein kinase CK2
[17]. CK2 targets CDC37 for phosphorylation contribut-
ing to the stabilization of the HSP90-CDC37 heterocom-
plex and recruitment of client proteins. In situ proximity
ligation-based analysis revealed attenuation of HSP90-
CDC37 interaction in cells treated with D11 suggesting
proteasome-mediated destabilization and degradation of
client proteins.
We evaluated effects mediated by D11 on the expres-
sion and activity levels of AMPK. The striking result that
emerged from this analysis was the finding that short ex-
posure to the compound leads to inhibition of AMPK al-
though a partial recovery occurs after 24 h treatment
(Fig. 3b). Defective AMPK activation has been shown in
some cancer cell types suggesting AMPK stimulation as
a novel therapeutic approach for cancer [58]. Paradoxic-
ally, we detected a basal activity level of AMPK in both
brain and pancreatic cancer cells suggesting that active
AMPK is essential for sustaining proliferation of these
cell lines. In support of our findings, recent studies have
shown that human glioblastoma cells, astrocytes and pros-
tate cancer cells carry activated AMPK that is required to
maintain cancer cell proliferation [60, 62]. Altogether, these
data indicate that the use of activators or inhibitors of
AMPK as a therapeutic approach in tumor cells has to be
carefully evaluated according to the biology of cancer cells.
The canonical NF-κB pathway was affected by D11
treatment. Data reported here show that D11 does reduce
the TNFα-stimulated transcriptional activity of NF-κB and
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the extent of inhibition depends on the cell type. As
D11 is not a direct inhibitor of IKKα/β [17], analysis of
components of the aforementioned pathway suggests
that inhibition of NF-κB results from D11-mediated tar-
geting of EGFR, CK2 and, possibly, NEMO (IKKγ). More-
over, it cannot be excluded that the HSP90-CDC37
heterocomplex might contribute to the regulation of
NF-κB as these proteins are part of the IKK complex and
required for TNFα-induced IKK activation (reviewed in
[65]).
Compelling evidence has underlined the importance of
the EGFR and NF-κB pathways in the regulation of tumor
Fig. 6 D11 treatment results in impaired cell migration and decreased expression of NKCC1. a M059K and MIA PaCa-2 cells were treated with
vehicle or D11 as indicated in the figure and subjected to wound-healing assay. D11 was added to the cells 4 h before the wounds were made.
Unwounded areas were measured as described in the Materials and methods (N = 6, *, P <0.05, **, P <0.0001). Original magnification: 50x. b Cells
were treated with D11 essentially as described in Fig. 4. Stimulation with IGF-1 was performed for 15 min. β-actin detection was carried out as
loading control. Experiments were repeated three times obtaining similar results
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cell migration and invasion, the latter by regulating the ex-
pression of matrix metalloproteinases [67]. We found that
D11 treatment significantly impairs migration of glioblast-
oma and pancreatic cancer cells that correlated with de-
creased expression levels of NKCC1 co-transporter. This
is consistent with results reported in previous studies
underlining the role of NKCC1 in the modulation of
glioblastoma cell volume and motility [57]. NKCC1 has
been shown to be an HSP90 interacting protein sug-
gesting that decreased expression of the co-transporter
might result from disruption of the HSP90-CDC37 het-
erocomplex and subsequent destabilization of NKCC1
client protein [15, 68].
Our group recently reported the identification of an-
other protein kinase CK2 inhibitor, E9, showing cytotoxic
effects on human hepatoma (HepG-2) and pancreatic car-
cinoma (Panc-1) cell lines with corresponding IC50 values
of 19 and 30 μM, respectively, [69]. In the future, as one
cannot exclude variability in cytotoxicity with different
cultured cell lines, it will be interesting to compare effects
induced by E9 and D11, respectively, with the cell lines
employed in this study.
Conclusions
Overall, we report evidence that D11 treatment induces
cell death and inhibits signaling pathways deregulated in
brain and pancreatic cancer cells, notably, the EGFR and
NF-κB signaling cascades. Exposure to D11 leads to: i)
down-regulation of EGFR expression levels, which may
represent a clear advantage for the treatment of certain
types of cancers carrying aberrant expression of this
growth factor receptor and ii) inhibition of cell motility
particularly important in the case of highly invasive cancer
cells [16, 70]. Data reported here underline the therapeutic
potential of this compound warranting further evaluation
with respect to multi-drug resistant cancer cells.
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Additional file 1: Figure S1. Viability analysis of U-87 MG cells. Cells
were treated with variable concentrations of D11 for the indicated times.
The proportion of viable cells is expressed in arbitrary units as a difference in
absorbance measured at 450 nm and 690 nm (reference) wavelengths,
respectively. Control cells were incubated with vehicle (0.1 % DMSO).
Asterisks denote statistical significant differences between control,
25 μM and 50 μM D11-treated cells for each time point, respectively,
(N = 6, *, P <0.0001). (JPEG 30 kb)
Additional file 2: Figure S2. FACS analysis of M059K and Mia PaCA-2
cells. Histogram representation of the Flow cytometry analysis of cells treated
as described in Fig. 1b. Quantification is shown in Fig. 1b. (JPEG 61 kb)
Additional file 3: Figure S3. Effect of D11 on NCS-induced cytotoxicity.
(a) M059K cells were treated with D11 and NCS as indicated in the figure.
Control experiment refers to cells treated with 0.1 % DMSO. Viability was
determined as described in Materials and methods. Values represent
mean +/− standard deviation from six samples for each treatment
condition. (b) M059K whole cell lysates were subjected to Western
blot analysis using an antibody against full-length and cleaved PARP.
Equal loading was verified by β-actin detection. (JPEG 42 kb)
Additional file 4: Figure S4. Western blot analysis of NF-κB protein
expression and phosphorylation levels. Whole cell extracts from U-87 MG
cells treated with vehicle or 50 μM D11 for 5 h and stimulated with 10 ng/ml
TNFα for 10 min prior to harvesting, were analyzed by immunoblotting
employing antibodies against NF-κB protein or the phosphorylated form at
S536 and S529, respectively. β-actin detection was used as loading control.
(JPEG 26 kb)
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